Coca-Cola is nearing a deal to buy a controlling stake in sports drink maker BodyArmor for $8 billion, which could be announced as early as Monday.
The late basketball icon Kobe Bryant was among BodyArmor’s earliest investors, buying a stake in 2013, just two years after it was launched.
According to Coca-Cola, it would not comment on the deal, regarding it as a mere rumor or speculation.
Coca-Cola bought a minority stake in BodyArmor in 2018 to become the brand’s second-largest shareholder.
The beverage giant has been focusing on its fast-moving beverages as consumers who are coming out of the come out of the pandemic are picking up more of its traditional sodas and flavored sparkling waters.
The company discontinued its Coca-Cola Energy drink in North America in May but kept its majority stake in Monster Beverage, one of the top energy drinks in the US.In 2018, Coca-Cola acquired coffee chain Costa for $5.1 billion to mark both a push into the coffee market and its first foray into retail chain operations.


Mexico President Claudia Sheinbaum Reconsiders Early School Closure Plan Ahead of 2026 World Cup
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
Los Angeles World Cup Security Plans: No ICE Immigration Enforcement at FIFA 2026 Matches, Officials Say
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Native American Groups Slam Trump’s Call to Restore Redskins Name
Oil Prices Slip but Stay on Track for Weekly Gains as U.S.-Iran Conflict Persists
U.S. Plans $115 Million Counter-Drone Investment to Secure FIFA World Cup and Major National Events
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
FIFA Defends Balogun Ban Suspension After Trump Praise Sparks World Cup Controversy
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Asian Stocks Slip as Iran Tensions, Samsung Weakness and Fed Caution Weigh on Markets
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 



